Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

UK Government will invest £30 million in innovative technology for NHS

On October 03, 2023, it was announced that UK patients across will benefit from a £30 million government investment in innovative medical technology, which will help ease pressures on the NHS this winter and could include the expansion of 3D checks that speed up cancer tests and novel logistics solutions such as the use of drones.

The Integrated care systems (ICSs) will be able to invest in the latest technology that can help cut waiting lists, speed up diagnosis, and deliver new and improved ways to treat patients. The ICSs could use the funding to expand virtual wards, allowing more patients to receive the care they need at home and freeing up hospital beds.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.